Submitted:
07 November 2023
Posted:
08 November 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Results
2.1. Docking
2.1.1. Working hypothesis, ligands and protein targets
2.1.2. Aggregated top scoring curcuminoid docking results on distinct CFTR ensembles
2.1.3. Identification of a consensus binding mode of curcumin available in the closed and open CFTR
2.2. Molecular Dynamics simulations
2.2.1. MD simulations of curcuminoids bound to the open and closed CFTR
2.2.2. MD-derived energies of interaction between curcuminoids and the distinct CFTR protein regions composing the consensus binding site
3. Discussion
4. Materials and Methods
4.1. Docking
4.2. MD simulations
5. Conclusions
Supplementary Materials
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Li, C.; Ramjeesingh, M.; Wang, W.; Garami, E.; Hewryk, M.; Lee, D.; Rommens, J.M.; Galley, K.; Bear, C.E. ATPase activity of the cystic fibrosis transmembrane conductance regula-tor. J Biol Chem. 1996, 271, 28463–8. [Google Scholar] [CrossRef] [PubMed]
- Ostedgaard, L.S.; Baldursson, O.; Vermeer, D.W.; Welsh, M.J.; Robertson, A.D. A functional R domain from cystic fibrosis transmembrane conductance regulator is predominantly unstructured in solution. Proc Natl Acad Sci U S A. 2000, 97, 5657–62. [Google Scholar] [CrossRef] [PubMed]
- Cheng, S.H.; Rich, D.P.; Marshall, J.; Gregory, R.J.; Welsh, M.J.; Smith, A.E. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell 1991, 66, 1027–36. [Google Scholar] [CrossRef] [PubMed]
- Mathews, C.J.; Tabcharani, J.A.; Chang, X.B.; Jensen, T.J.; Riordan, J.R.; Hanrahan, J.W. Di-basic protein kinase A sites regulate bursting rate and nucleotide sensitivity of the cystic fibrosis transmembrane conductance regulator chloride channel. J Physiol. 1998, 508, 365–77. [Google Scholar] [CrossRef] [PubMed]
- Mense, M.; Vergani, P.; White, D.M.; Altberg, G.; Nairn, A.C.; Gadsby, D.C. In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer. EMBO J. 2006, 25, 4728–39. [Google Scholar] [CrossRef]
- Chappe, V.; Hinkson, D.A.; Zhu, T.; Chang, X.B.; Riordan, J.R.; Hanrahan, J.W. Phosphorylation of protein kinase C sites in NBD1 and the R domain control CFTR channel activation by PKA. J Physiol. 2003, 548, 39–52. [Google Scholar] [CrossRef] [PubMed]
- Wang, W.; Bernard, K.; Li, G.; Kirk, K.L. Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J Biol Chem. 2007, 282, 4533–4544. [Google Scholar] [CrossRef] [PubMed]
- Cui, L.; Aleksandrov, L.; Chang, X.B.; Hou, Y.X.; He, L.; Hegedus, T.; Gentzsch, M.; Aleksandrov, A.; Balch, W.E.; Riordan, J.R. Domain interdependence in the biosynthetic assembly of CFTR. J Mol Biol. 2007, 365, 981–94. [Google Scholar] [CrossRef]
- Zielenski, J.; Tsui, L.C. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet. 1995, 29, 777–807. [Google Scholar] [CrossRef] [PubMed]
- Davis, P.B. Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2006, 173, 475–82. [Google Scholar] [CrossRef]
- Bacalhau, M.; Camargo, M.; Magalhães-Ghiotto, G.A.V.; Drumond, S.; Castelletti, C.H.M.; Lopes-Pacheco, M. Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis. Pharmaceuticals (Basel) 2023, 16, 410. [Google Scholar] [CrossRef] [PubMed]
- Sohma, Y.; Yu, Y.C.; Hwang, T.C. Curcumin and genistein: the combined effects on disease-associated CFTR mutants and their clinical implications. Curr Pharm Des. 2013, 19, 3521–8. [Google Scholar] [CrossRef] [PubMed]
- Baharara, H.; Kesharwani, P.; Johnston, T.P.; Sahebkar, A. Therapeutic potential of phytochemicals for cystic fibrosis. Biofactors 2023, 49, 984–1009. [Google Scholar] [CrossRef] [PubMed]
- Dekkers, J.F.; Van Mourik, P.; Vonk, A.M.; Kruisselbrink, E.; Berkers, G.; de Winter-de Groot, K.M.; Janssens, H.M.; Bronsveld, I.; van der Ent, C.K.; de Jonge, H.R.; Beekman, J.M. Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR muta-tions. J Cyst Fibros. 2016, 15, 568–78. [Google Scholar] [CrossRef] [PubMed]
- Egan, M.E.; Pearson, M.; Weiner, S.A.; Rajendran, V.; Rubin, D.; Glöckner-Pagel, J.; Canny, S.; Du, K.; Lukacs, G.L.; Caplan, M.J. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004, 304, 600–2. [Google Scholar] [CrossRef] [PubMed]
- Henke, D.C. Cystic fibrosis bench to bedside for Curcuma longa L. in cystic fibrosis – Curcumin’s controversial role as therapy. US Respir. Dis. 2008, 4, 76–78. [Google Scholar]
- Dey, I.; Shah, K.; Bradbury, N.A. Natural Compounds as Therapeutic Agents to Treat Cystic Fibrosis. JSM Gastroenterology and Hepatology 2016, 4, 1054. [Google Scholar]
- Wang, Y.J.; Pan, M.H.; Cheng, A.L.; Lin, L.I.; Ho, Y.S.; Hsieh, C.Y.; Lin, J.K. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997, 15, 1867–76. [Google Scholar] [CrossRef] [PubMed]
- Manolova, Y.; Deneva, V.; Antonov, L.; Drakalska, E.; Momekova, D.; Lambov, N. The effect of the water on the curcumin tautomerism: a quantitative approach. Spectrochim Acta A Mol Biomol Spectrosc. 2014, 132, 815–20. [Google Scholar] [CrossRef] [PubMed]
- Puglisi, A.; Giovannini, T.; Antonov, L.; Cappelli, C. Interplay between conformational and solvent effects in UV-visible absorption spectra: curcumin tautomers as a case study. Phys Chem Chem Phys. 2019, 21, 15504–15514. [Google Scholar] [CrossRef]
- Kaur, R.; Khullar, P.; Mahal, A.; Gupta, A.; Singh, N.; Ahluwalia, G.K.; Bakshi, M.S. Keto-Enol Tautomerism of Temperature and pH Sensitive Hydrated Curcumin Nanoparticles: Their Role as Nanoreactors and Compatibility with Blood Cells. J Agric Food Chem. 2018, 66, 11974–11980. [Google Scholar] [CrossRef] [PubMed]
- Quispe, C.; Herrera-Bravo, J.; Khan, K.; Javed, Z.; Semwal, P.; Painuli, S.; Kamiloglu, S.; Martorell, M.; Calina, D.; Sharifi-Rad, J. Therapeutic applications of curcumin nanomedicine formulations in cystic fibrosis. Prog Biomater. 2022, 11, 321–329. [Google Scholar] [CrossRef] [PubMed]
- Rafeey, M.; Nikniaz, Z.; FarshiRadvar, F.; Sameni, Z.; Faramarzi, E. Effects of Curcumin Supplementation on Quality of Life of Cystic Fibrosis Patients. International Journal of Pediatrics 2020, 8, 11169–11176. [Google Scholar] [CrossRef]
- Wang, G. Molecular Basis for Fe(III)-Independent Curcumin Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Activity. Biochemistry 2015, 54, 2828–40. [Google Scholar] [CrossRef] [PubMed]
- Bernard, K.; Wang, W.; Narlawar, R.; Schmidt, B.; Kirk, K.L. Curcumin cross-links cystic fibrosis transmembrane conductance regulator (CFTR) polypeptides and potentiates CFTR channel activity by distinct mechanisms. J Biol Chem. 2009, 284, 30754–65. [Google Scholar] [CrossRef] [PubMed]
- ten Brink, T.; Exner, T.E. Influence of protonation, tautomeric, and stereoisomeric states on protein-ligand docking results. J Chem Inf Model 2009, 49, 1535–46. [Google Scholar] [CrossRef] [PubMed]
- Korb, O.; Stützle, T.; Exner, T.E. Empirical scoring functions for advanced protein-ligand docking with PLANTS. J Chem Inf Model 2009, 49, 84–96. [Google Scholar] [CrossRef]
- Kalé, L.; Skeel, R.; Bhandarkar, M.; Brunner, R.; Gursoy, A.; Krawetz, N.; Phillips, J.; Shinozaki, A.; Varadarajan, K.; Schulten, K. NAMD2: Greater Scalability for Parallel Molecular Dynamics. J Comput Phys. 1999, 151, 283–312. [Google Scholar] [CrossRef]
- Phillips, J.C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R.D.; Kalé, L.; Schulten, K. Scalable molecular dynamics with NAMD. J Comput Chem. 2005, 26, 1781–802. [Google Scholar] [CrossRef]
- MacKerell, A.D.; Bashford, D.; Bellott, M.; Dunbrack, R.L.; Evanseck, J.D.; Field, M.J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph-McCarthy, D.; Kuchnir, L.; Kuczera, K.; Lau, F.T.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D.T.; Prodhom, B.; Reiher, W.E.; Roux, B.; Schlenkrich, M.; Smith, J.C.; Stote, R.; Straub, J.; Watanabe, M.; Wiórkiewicz-Kuczera, J.; Yin, D.; Karplus, M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B. 1998, 102, 3586–616. [Google Scholar] [CrossRef]
- Vanommeslaeghe, K.; Hatcher, E.; Acharya, C.; Kundu, S.; Zhong, S.; Shim, J.; Darian, E.; Guvench, O.; Lopes, P.; Vorobyov, I.; Mackerell, A.D., Jr. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem. 2010, 31, 671–90. [Google Scholar] [CrossRef] [PubMed]
- Zoete, V.; Cuendet, M.A.; Grosdidier, A.; Michielin, O. SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem. 2011, 32, 2359–68. [Google Scholar] [CrossRef] [PubMed]
- Humphrey, W.; Dalke, A.; Schulten, K. VMD: visual molecular dynamics. J Mol Graph. 1996, 14, 33–88, 27-8. [Google Scholar] [CrossRef] [PubMed]









Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).